Dermata Therapeutics (DRMA) Registration filing summary

Company overview and business model

• Focuses on developing and commercializing science-backed dermatology products for common and underserved skin conditions, with a recent strategic shift from prescription (Rx) to over-the-counter (OTC) products leveraging proprietary Spongilla technology.

• Plans to launch a once-weekly topical acne kit in mid-2026, combining Spongilla technology with FDA-approved OTC ingredients like salicylic acid.

• Aims to address broad consumer segments by offering accessible, effective, and affordable OTC treatments for acne, psoriasis, seborrheic dermatitis, and other skin diseases.

• Exploring the use of Spongilla technology as a platform for enhanced topical delivery of large molecules, such as botulinum toxin, for both medical and aesthetic applications.

Financial performance and metrics

• Has not generated any revenue from product sales to date and has a limited operating history focused on R&D and clinical trials.

• Reported net losses of $5.7 million for the nine months ended September 30, 2025, and $9.1 million for the same period in 2024; accumulated deficit of $71.4 million as of September 30, 2025.

• Raised approximately $77.5 million in gross proceeds from debt and equity sales since inception.

• Expects continued significant expenses and operating losses as it prepares for commercial launch and expands R&D and marketing activities.

Use of proceeds and capital allocation

• Net proceeds from securities sales and any exercise of convertible securities will be used for working capital and general corporate purposes.

• Pending use, proceeds will be invested in short-term, interest-bearing instruments or other investment-grade securities.